Ensysce Biosciences (ENSC) Expected to Announce Quarterly Earnings on Monday

Ensysce Biosciences (NASDAQ:ENSC) is projected to release its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.99) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 4:00 PM ET.

Ensysce Biosciences Trading Up 57.8%

NASDAQ ENSC opened at $0.62 on Monday. Ensysce Biosciences has a twelve month low of $0.31 and a twelve month high of $5.72. The stock has a 50-day moving average of $0.76 and a 200 day moving average of $1.57. The stock has a market capitalization of $2.26 million, a price-to-earnings ratio of -0.10 and a beta of 1.14.

Institutional Investors Weigh In On Ensysce Biosciences

Several large investors have recently bought and sold shares of the company. Citadel Advisors LLC purchased a new position in shares of Ensysce Biosciences in the third quarter valued at approximately $34,000. Virtu Financial LLC acquired a new position in Ensysce Biosciences in the 3rd quarter valued at $34,000. DRW Securities LLC raised its stake in Ensysce Biosciences by 42.4% in the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in Ensysce Biosciences by 100.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares in the last quarter. 5.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.